Qiagen (NYSE:QGEN) Issues FY 2026 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 2.430- for the period, compared to the consensus estimate of 2.430. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.2 billion.

Qiagen Price Performance

Shares of Qiagen stock traded up $0.55 on Friday, hitting $42.28. The company’s stock had a trading volume of 3,214,582 shares, compared to its average volume of 2,438,691. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. The firm has a fifty day moving average price of $39.32 and a 200-day moving average price of $41.69. The company has a market capitalization of $8.71 billion, a P/E ratio of 21.66, a price-to-earnings-growth ratio of 4.19 and a beta of 0.63.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. The firm had revenue of $535.04 million for the quarter, compared to analysts’ expectations of $527.50 million. During the same period in the prior year, the company earned $0.60 EPS. The firm’s revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, equities research analysts expect that Qiagen will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were given a $0.35 dividend. This is a boost from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 90.0%. The ex-dividend date was Tuesday, July 7th. Qiagen’s dividend payout ratio (DPR) is currently 18.32%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on QGEN shares. Kepler Capital Markets set a $38.60 price objective on shares of Qiagen and gave the stock a “hold” rating in a research note on Thursday, June 25th. Citigroup reaffirmed a “hold” rating on shares of Qiagen in a research note on Monday, May 18th. Berenberg Bank set a $45.50 target price on Qiagen and gave the company a “hold” rating in a report on Tuesday, July 14th. Barclays set a $40.00 price target on Qiagen and gave the stock an “equal weight” rating in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $43.00 price target on shares of Qiagen in a report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $43.34.

Hedge Funds Weigh In On Qiagen

Institutional investors have recently modified their holdings of the company. Danske Bank A S acquired a new stake in Qiagen during the third quarter worth approximately $36,000. Global Retirement Partners LLC raised its holdings in Qiagen by 279.9% in the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after acquiring an additional 851 shares during the last quarter. Advisory Services Network LLC purchased a new position in shares of Qiagen during the 3rd quarter worth $64,000. Kestra Advisory Services LLC purchased a new position in shares of Qiagen during the 4th quarter worth $70,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Qiagen during the fourth quarter worth $73,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.